James D.  Swanson net worth and biography

James Swanson Biography and Net Worth

Insider of Johnson & Johnson

Jim Swanson is Executive Vice President, Chief Information Officer, and member of the Executive Committee for Johnson & Johnson. Based at Johnson & Johnson’s USA headquarters, Jim is responsible for accelerating Johnson & Johnson’s business outcomes and advancing human health with technology and digital innovation.

In his current role, Jim leads the Johnson & Johnson Technology organization, a team of more than 4,000 professionals across 50 countries who are passionate about combining deep scientific expertise with the latest digital solutions to confront some of the most complex healthcare challenges of our time. In addition, Jim and his team are responsible for powering the 144,000 colleagues across Johnson & Johnson and the digital ecosystem that connects the Company to patients and customers.

Jim has an overriding commitment to attracting and growing digital talent across the enterprise and forging external connections across industries and disciplines. He has been known to say he has “the best job in the world” because of his ability to drive positive impact in the world using “tech for good”. Jim, and the organizations he has led, have received industry accolades for their contributions in leadership, application of technology to drive outcomes and deliver business value, best places to work in IT, and support of STEM for emerging talent.

Jim rejoined Johnson & Johnson in 2019 from Bayer Crop Science, where he served as a member of the Executive Leadership Team, Chief Information Officer, and Head of Digital Transformation. Previously, he served as Chief Information Officer at Monsanto for five years, before the company was acquired by Bayer. Prior to that role, Jim spent nine years working as Vice President and Chief Information Officer for Johnson & Johnson Pharmaceutical, where he advanced technology throughout the company’s Research & Development organization.

Earlier in his career, Jim led the Research & Development and Commercial IT organizations at Merck. Jim began as a bench scientist at SmithKline Beecham before transitioning to IT. Throughout his professional life, he has had extensive international experience, including living in the United Kingdom and Germany.

Jim holds a bachelor's degree in Bioscience and Biotechnology and a master's degree in Computer Science, both from Drexel University.

Jim is married and is the proud father of three daughters. In his free time, he enjoys running, biking, skiing, scuba diving, and boating, as well as volunteering with United Way Ready by 21 and the American Heart Association.

What is James D. Swanson's net worth?

The estimated net worth of James D. Swanson is at least $1.34 million as of March 6th, 2023. Mr. Swanson owns 9,215 shares of Johnson & Johnson stock worth more than $1,341,151 as of June 15th. This net worth estimate does not reflect any other assets that Mr. Swanson may own. Learn More about James D. Swanson's net worth.

How old is James D. Swanson?

Mr. Swanson is currently 58 years old. There are 6 older executives and no younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Dr. John C. Reed M.D., Ph.D., Executive Vice President of Innovative Medicine, R&D, who is 66 years old. Learn More on James D. Swanson's age.

How do I contact James D. Swanson?

The corporate mailing address for Mr. Swanson and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on James D. Swanson's contact information.

Has James D. Swanson been buying or selling shares of Johnson & Johnson?

James D. Swanson has not been actively trading shares of Johnson & Johnson during the last quarter. Most recently, James D. Swanson sold 1,062 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a transaction totalling $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares of the company's stock, valued at $1,425,191.90. Learn More on James D. Swanson's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (Insider), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 4 times. They sold a total of 97,820 shares worth more than $15,312,567.44. The most recent insider tranaction occured on February, 16th when Major Shareholder & Johnson Johnson sold 3,725 shares worth more than $96,142.25. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 2/16/2024.

James D. Swanson Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2023Sell1,062$154.66$164,248.929,215View SEC Filing Icon  
See Full Table

James D. Swanson Buying and Selling Activity at Johnson & Johnson

This chart shows James D Swanson's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $145.54
Low: $144.48
High: $145.97

50 Day Range

MA: $148.38
Low: $144.40
High: $154.68

2 Week Range

Now: $145.54
Low: $143.13
High: $175.97

Volume

4,075,342 shs

Average Volume

7,121,075 shs

Market Capitalization

$350.27 billion

P/E Ratio

9.07

Dividend Yield

3.41%

Beta

0.53